Skip to Content
Merck
All Photos(1)

Documents

SML2589

Sigma-Aldrich

Dasatinib

≥98% (HPLC), powder, protein kinases inhibitor

Synonym(s):

BMS 354825, BMS-354825, BMS354825, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H26ClN7O2S
CAS Number:
Molecular Weight:
488.01
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Dasatinib, ≥98% (HPLC)

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1

InChI

1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

InChI key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Dasatinib has been used:
  • as a protein kinase inhibitor to study its effects on macrophage polarization, lipogenesis, western diet-induced progression of simple steatosis into steatohepatitis (NASH), and liver fibrosis in mice
  • as an SRC tyrosine kinase inhibitor to study its effects on hepatocellular carcinoma cells
  • as a tyrosine kinase inhibitor to study its effects on autophagy in neuronal cells

Biochem/physiol Actions

Dasatinib is a thiazole-carboxamide compound that inhibits a broad spectrum of protein kinases such as breakpoint cluster region-tyrosine protein kinase ABL (Bcr-Abl), Btk family members, platelet-derived growth factor receptor α/β (PDGFR-α/β), and ephrin receptor kinase. It also inhibits Src-family kinases such as SRC tyrosine kinase, and lymphocyte-specific protein kinase (LCK). Dasatinib exhibits certain effects on hematopoietic cells like suppressing natural killer cell toxicity, inhibiting T lymphocytes activation and proliferation, and influencing platelet activation. It is also studied in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

Signal Word

Danger

Hazard Classifications

Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

Target Organs

Gastro-intestinal system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Khushwant S Bhullar et al.
Food chemistry. Molecular sciences, 4, 100069-100069 (2022-04-14)
Dasatinib, a small-molecule drug used as a treatment for chronic myeloid leukemia induces mitochondrial damage in embryonic kidney (293 T) cells (p < 0.05). This dasatinib induced mitochondrial injury in kidney cells was mitigated by H3K36me3 activating ovotransferrin-derived peptides GWN and GW. Pre-treatment
Liat Bar-On et al.
PloS one, 18(12), e0294176-e0294176 (2023-12-27)
SARS-CoV-2 infection elicits robust CD8 T-cell responses, yet the identity of the mechanisms playing dominant roles in initiating the virus-specific CD8 T-cell responses are largely unknown. In the present study, we interrogate the contribution of the cDC1 subset to SARS-CoV-2-specific
Hassan Reda Hassan Elsayed et al.
Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft, 234, 151626-151626 (2020-11-05)
Non-alcoholic fatty liver disease (NAFLD) is a worldwide disease that progresses into steatohepatitis (NASH) that has no current effective treatment. This study aimed, for the first time, to investigate the effect of Dasatinib; a tyrosine kinase inhibitor showing anti-PDGFR activity
Markus Lindauer et al.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 212, 29-68 (2018-08-03)
Dasatinib is an oral available short-acting inhibitor of multiple tyrosine kinases. It was designed to inhibit ABL and SRC, but also has activity in multiple other kinases, including c-KIT, PDGFR-α, PDGFR-β, and ephrin receptor kinases. Dasatinib is a very potent inhibitor
Hassan Reda Hassan Elsayed et al.
Cells, 11(4) (2022-02-26)
Obesity causes renal changes (ORC), characterized by defective renal autophagy, lipogenesis, enhanced macrophage infiltration and apoptosis. We hypothesize that Dasatinib, a tyrosine kinase inhibitor, may ameliorate changes associated with obesity. We the mice with either Obesogenic diet (OD) or a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service